Related references
Note: Only part of the references are listed.Effect of Gemcitabine based chemotherapy on the immunogenicity of pancreatic tumour cells and T-cells
P. L. Smith et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2021)
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
Caicun Zhou et al.
LANCET RESPIRATORY MEDICINE (2021)
Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer A Phase 2 Nonrandomized Clinical Trial
Emese Zsiros et al.
JAMA ONCOLOGY (2021)
Neoadjuvant Chemotherapy Induces IL34 Signaling and Promotes Chemoresistance via Tumor-Associated Macrophage Polarization in Esophageal Squamous Cell Carcinoma
Shotaro Nakajima et al.
MOLECULAR CANCER RESEARCH (2021)
Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer
Davide Melisi et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Immune monitoring in mesothelioma patients identifies novel immune-modulatory functions of gemcitabine associating with clinical response
Floris Dammeijer et al.
EBIOMEDICINE (2021)
Trials and tribulations of pancreatic cancer immunotherapy
Daniel R. Principe et al.
CANCER LETTERS (2021)
Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial
Keunchil Park et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
Nancy Y Lee et al.
LANCET ONCOLOGY (2021)
Combined Gemcitabine and Immune-Checkpoint Inhibition Conquers Anti-PD-L1 Resistance in Low-Immunogenic Mismatch Repair-Deficient Tumors
Inken Salewski et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction (G/GEJ) cancer: Initial findings of the global phase 3 KEYNOTE-811 study.
Yelena Y. Janjigian et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
Jong-Mu Sun et al.
LANCET (2021)
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
Yelena Y. Janjigian et al.
LANCET (2021)
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
Thomas Powles et al.
LANCET ONCOLOGY (2021)
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study
Eric Pujade-Lauraine et al.
LANCET ONCOLOGY (2021)
Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial
Bradley J. Monk et al.
LANCET ONCOLOGY (2021)
T Cell-Mediated Antitumor Immunity Cooperatively Induced By TGFβR1 Antagonism and Gemcitabine Counteracts Reformation of the Stromal Barrier in Pancreatic Cancer
Dandan Li et al.
MOLECULAR CANCER THERAPEUTICS (2021)
Bortezomib Induces Anti-Multiple Myeloma Immune Response Mediated by cGAS/STING Pathway Activation
Annamaria Gulla et al.
BLOOD CANCER DISCOVERY (2021)
Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion
Suchit Jhunjhunwala et al.
NATURE REVIEWS CANCER (2021)
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
Peter Schmid et al.
LANCET ONCOLOGY (2020)
Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study
Suneel D. Kamath et al.
ONCOLOGIST (2020)
Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer
S. Adams et al.
ANNALS OF ONCOLOGY (2020)
NK cells for cancer immunotherapy
Noriko Shimasaki et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Resistance to Checkpoint Inhibition in Cancer Immunotherapy
Luisa Barrueto et al.
TRANSLATIONAL ONCOLOGY (2020)
Platinum Derivatives Effects on Anticancer Immune Response
Cedric Rebe et al.
BIOMOLECULES (2020)
Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open -label phase III study
R. L. Ferris et al.
ANNALS OF ONCOLOGY (2020)
Changes in Tumor-infiltrating Lymphocytes After Neoadjuvant Chemotherapy and Clinical Significance in Triple Negative Breast Cancer
Hyun Lee et al.
ANTICANCER RESEARCH (2020)
Long-Term Gemcitabine Treatment Reshapes the Pancreatic Tumor Microenvironment and Sensitizes Murine Carcinoma to Combination Immunotherapy
Daniel R. Principe et al.
CANCER RESEARCH (2020)
Low-Dose Gemcitabine Treatment Enhances Immunogenicity and Natural Killer Cell-Driven Tumor Immunity in Lung Cancer
Xin Zhang et al.
FRONTIERS IN IMMUNOLOGY (2020)
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
Matthew D. Galsky et al.
LANCET (2020)
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study
Jing Huang et al.
LANCET ONCOLOGY (2020)
FOLFOX Chemotherapy Ameliorates CD8 T Lymphocyte Exhaustion and Enhances Checkpoint Blockade Efficacy in Colorectal Cancer
Yue Guan et al.
FRONTIERS IN ONCOLOGY (2020)
Tumor-infiltrating Lymphocyte Score Based on FDG PET/CT for Predicting the Effect of Neoadjuvant Chemotherapy in Breast Cancer
Shinsuke Sasada et al.
ANTICANCER RESEARCH (2020)
A decade of immune-checkpoint inhibitors in cancer therapy
Caroline Robert
NATURE COMMUNICATIONS (2020)
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
Takashi Kojima et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
Elizabeth A. Mittendorf et al.
LANCET (2020)
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial
Kohei Shitara et al.
JAMA ONCOLOGY (2020)
The outstanding antitumor capacity of CD4+ T helper lymphocytes
Tong Li et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2020)
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Javier Cortes et al.
LANCET (2020)
Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy
Chia-Sing Lu et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Phase I study of nivolumab (Nivo) plus nab-paclitaxel (nab-P) plus gemcitabine (Gem) in advanced pancreatic cancer (APC).
Zev A. Wainberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Oxaliplatin Treatment Alters Systemic Immune Responses
Vanesa Stojanovska et al.
BIOMED RESEARCH INTERNATIONAL (2019)
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
Martin Reck et al.
LANCET RESPIRATORY MEDICINE (2019)
Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial
Hyun Cheol Chung et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines?
Christine Menetrier-Caux et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study
U. A. Matulonis et al.
ANNALS OF ONCOLOGY (2019)
Cisplatin Augments Antitumor T-Cell Responses Leading to a Potent Therapeutic Effect in Combination With PD-L1 Blockade
Daiko Wakita et al.
ANTICANCER RESEARCH (2019)
Variation of Programmed Death Ligand 1 Expression After Platinum-based Neoadjuvant Chemotherapy in Lung Cancer
Lei Guo et al.
JOURNAL OF IMMUNOTHERAPY (2019)
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
Howard West et al.
LANCET ONCOLOGY (2019)
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Filipe Martins et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Neoadjuvant Chemotherapy Increases PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Esophageal Squamous Cell Carcinoma
Eiji Fukuoka et al.
ANTICANCER RESEARCH (2019)
Emerging strategies in cancer therapy combining chemotherapy with immunotherapy
Qiuhua Luo et al.
CANCER LETTERS (2019)
Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use
Robert L. Ferris et al.
CLINICAL CANCER RESEARCH (2019)
Immunogenic cell death in cancer therapy: Present and emerging inducers
Jingyi Zhou et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2019)
Cytotoxic Chemotherapy as an Immune Stimulus: A Molecular Perspective on Turning Up the Immunological Heat on Cancer
James W. Opzoomer et al.
FRONTIERS IN IMMUNOLOGY (2019)
Immunogenic Cell Death and Immunotherapy of Multiple Myeloma
Alfonso Serrano-del Valle et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2019)
The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy
David A. Schaer et al.
CLINICAL CANCER RESEARCH (2019)
CD4 T cells target colorectal cancer antigens upregulated by oxaliplatin
Jeanne Galaine et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer
So-Jin Park et al.
ORAL ONCOLOGY (2019)
Neoadjuvant cisplatin and paclitaxel modulate tumor-infiltrating T cells in patients with cervical cancer
A. Marijne Heeren et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Luis Paz-Ares et al.
LANCET (2019)
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Barbara Burtness et al.
LANCET (2019)
Drug-induced PD-L1 expression and cell stress response in breast cancer cells can be balanced by drug combination
Yosi Gilad et al.
SCIENTIFIC REPORTS (2019)
Clinical significance of tumor- infiltrating lymphocytes and neutrophil-to-lymphocyte ratio in patients with stage III colon cancer who underwent surgery followed by FOLFOX chemotherapy
Yoon Jin Cha et al.
SCIENTIFIC REPORTS (2019)
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
T. A. Chan et al.
ANNALS OF ONCOLOGY (2019)
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
Satya Das et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Induction of Peripheral Effector CD8 T-cell Proliferation by Combination of Paclitaxel, Carboplatin, and Bevacizumab in Non-small Cell Lung Cancer Patients
Pauline L. de Goeje et al.
CLINICAL CANCER RESEARCH (2019)
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
Ezra E. W. Cohen et al.
LANCET (2019)
TGFβ Blockade Augments PD-1 Inhibition to Promote T-Cell-Mediated Regression of Pancreatic Cancer
Daniel R. Principe et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles
Shannon Grabosch et al.
ONCOGENE (2019)
Suppression of chemotherapy-induced cytokine/lipid mediator surge and ovarian cancer by a dual COX-2/sEH inhibitor
Allison Gartung et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer
Junghoon Shin et al.
CANCER RESEARCH AND TREATMENT (2019)
Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus The Phase 2 KEYNOTE-180 Study
Manish A. Shah et al.
JAMA ONCOLOGY (2019)
Macrophages as regulators of tumour immunity and immunotherapy
David G. DeNardo et al.
NATURE REVIEWS IMMUNOLOGY (2019)
Immunomodulatory effects of chemotherapy on blood lymphocytes and survival of patients with advanced non-small cell lung cancer
Mohanad Aldarouish et al.
INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY (2019)
Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma
Glen J. Weiss et al.
INVESTIGATIONAL NEW DRUGS (2018)
Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer
Erta Kalanxhi et al.
BRITISH JOURNAL OF CANCER (2018)
Impact of 5-Fu/oxaliplatin on mouse dendritic cells and synergetic effect with a colon cancer vaccine
Xinqiang Hong et al.
CHINESE JOURNAL OF CANCER RESEARCH (2018)
Docetaxel promotes the generation of anti-tumorigenic human macrophages
Camilla Rydberg Millrud et al.
EXPERIMENTAL CELL RESEARCH (2018)
T-cell modulation by cyclophosphamide for tumour therapy
Ellyn Hughes et al.
IMMUNOLOGY (2018)
Safety and Antitumor Activity of the Anti-Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma
Toshihiko Doi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Gemcitabine directly inhibits effector CD4 T cell activation and prevents experimental autoimmune encephalomyelitis
Justin D. Glenn et al.
JOURNAL OF NEUROIMMUNOLOGY (2018)
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
Thomas Powles et al.
LANCET (2018)
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
Manish R. Patel et al.
LANCET ONCOLOGY (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Cyclophosphamide-modified murine peritoneal macrophages induce CD4+ T contrasuppressor cells that protect contact sensitivity T effector cells from suppression
Monika Majewska-Szczepanik et al.
PHARMACOLOGICAL REPORTS (2018)
Gemcitabine alters the proteasome composition and immunopeptidome of tumour cells
A. M. Gravett et al.
ONCOIMMUNOLOGY (2018)
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer Phase 2 Clinical KEYNOTE-059 Trial
Charles S. Fuchs et al.
JAMA ONCOLOGY (2018)
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
Yelena Y. Janjigian et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study
Fabrice Barlesi et al.
LANCET ONCOLOGY (2018)
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
L. Horn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
L. Paz-Ares et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Chemotherapeutic Treatments Increase PD-L1 Expression in Esophageal Squamous Cell Carcinoma through EGFR/ERK Activation
Hai Yan Ng et al.
TRANSLATIONAL ONCOLOGY (2018)
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Spencer C. Wei et al.
CANCER DISCOVERY (2018)
Gemcitabine treatment promotes immunosuppressive microenvironment in pancreatic tumors by supporting the infiltration, growth, and polarization of macrophages
Sachin Kumar Deshmukh et al.
SCIENTIFIC REPORTS (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
RAS status and neoadjuvant chemotherapy impact CD8+cells and tumor HLA class I expression in liver metastatic colorectal cancer
Fanny Ledys et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
The Canadian Cancer Trials Group PA. 7 trial: Results from the safety run in of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) versus GEM, nab-P, durvalumab (D), and tremelimumab (T) as first-line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).
Daniel John Renouf et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Immune checkpoint inhibitors: recent progress and potential biomarkers
Pramod Darvin et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2018)
Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy
Charlotte S. Lo et al.
CLINICAL CANCER RESEARCH (2017)
Phase I study of nivolumab (nivo) plus nab-paclitaxel (nab-P) ± gemcitabine (Gem) in solid tumors: Interim results from the pancreatic cancer (PC) cohorts.
Zev A. Wainberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastroesophageal junction cancer (AGC): A double-blinded, randomized, phase III trial.
Yoon-Koo Kang et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A phase Ib/II pilot trial with nab-paclitaxel plus gemcitabine plus cisplatin in patients (pts) with stage IV pancreatic cancer.
Gayle S. Jameson et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
Joshua Bauml et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Yoon-Koo Kang et al.
LANCET (2017)
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
Arjun V. Balar et al.
LANCET (2017)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial
Toshihiro Kudo et al.
LANCET ONCOLOGY (2017)
Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial
James L. Gulley et al.
LANCET ONCOLOGY (2017)
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
Arjun V. Balar et al.
LANCET ONCOLOGY (2017)
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
Padmanee Sharma et al.
LANCET ONCOLOGY (2017)
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
J. Bellmunt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Chemotherapy
Reza Nejati et al.
PANCREAS (2017)
Dysregulation of cytokine mediated chemotherapy induced cognitive impairment
Xiaojia Ren et al.
PHARMACOLOGICAL RESEARCH (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism
George S. Karagiannis et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma
Linda Tran et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Inflammatory cytokine production in tumor cells upon chemotherapy drug exposure or upon selection for drug resistance
Derek W. Edwardson et al.
PLOS ONE (2017)
Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes and residual cancer burden
Yuka Asano et al.
BMC CANCER (2017)
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus)
Glen J. Weiss et al.
BRITISH JOURNAL OF CANCER (2017)
Effect of paclitaxel and carboplatin on tumor-reactive T cells and the efficacy of PD-1 blockade.
Yiyi Yan et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Immunogenic cell death in cancer and infectious disease
Lorenzo Galluzzi et al.
NATURE REVIEWS IMMUNOLOGY (2017)
MHC class I chain-related molecule A and B expression is upregulated by cisplatin and associated with good prognosis in patients with non-small cell lung cancer
Riki Okita et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Tumor Eradication by Cisplatin Is Sustained by CD80/86-Mediated Costimulation of CD8+ T Cells
Elham Beyranvand Nejad et al.
CANCER RESEARCH (2016)
Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
Naiyer A. Rizvi et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancer
Emma Eriksson et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2016)
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Louis Fehrenbacher et al.
LANCET (2016)
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
Geoffrey T. Gibney et al.
LANCET ONCOLOGY (2016)
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
Corey J. Langer et al.
LANCET ONCOLOGY (2016)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Tumor-infiltrating lymphocytes in breast cancer predict the response to chemotherapy and survival outcome: A meta-analysis
Ke Wang et al.
ONCOTARGET (2016)
Ipilimumab and gemcitabine for advanced pancreas cancer: A phase Ib study.
Aparna Kalyan et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer
Rashmi Verma et al.
BREAST CANCER RESEARCH (2016)
Association of proinflammatory cytokines and chemotherapy-associated cognitive impairment in breast cancer patients: a multi-centered, prospective, cohort study
Y. T. Cheung et al.
ANNALS OF ONCOLOGY (2015)
STAT3 Inhibition Enhances the Therapeutic Efficacy of Immunogenic Chemotherapy by Stimulating Type 1 Interferon Production by Cancer Cells
Heng Yang et al.
CANCER RESEARCH (2015)
Suppressive effects of gemcitabine plus cisplatin chemotherapy on regulatory T cells in nonsmall-cell lung cancer
Cheng Chen et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2015)
Survival in Patients With Severe Lymphopenia Following Treatment With Radiation and Chemotherapy for Newly Diagnosed Solid Tumors
Stuart A. Grossman et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Contrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in Non-Small-Cell Lung Cancer Cells
Riki Okita et al.
PLOS ONE (2015)
Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy
Jennifer A. Wargo et al.
SEMINARS IN ONCOLOGY (2015)
A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer
M. Aglietta et al.
ANNALS OF ONCOLOGY (2014)
Sensitizing Protective Tumor Microenvironments to Antibody-Mediated Therapy
Christian P. Pallasch et al.
CELL (2014)
Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer
L. Bracci et al.
CELL DEATH AND DIFFERENTIATION (2014)
Cisplatin-Induced Antitumor Immunomodulation: A Review of Preclinical and Clinical Evidence
Andreas R. de Biasi et al.
CLINICAL CANCER RESEARCH (2014)
Gemcitabine-treated pancreatic cancer cell medium induces the specific CTL antitumor activity by stimulating the maturation of dendritic cells
Qingshan Pei et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2014)
Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
Antonella Sistigu et al.
NATURE MEDICINE (2014)
Chemotherapy Enhances Cross-Presentation of Nuclear Tumor Antigens
Chidozie C. Anyaegbu et al.
PLOS ONE (2014)
Selective Depletion of Regulatory T Cell Subsets by Docetaxel Treatment in Patients with Nonsmall Cell Lung Cancer
Jie-Yao Li et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2014)
Screening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity Set
Abdul Qader Sukkurwala et al.
ONCOIMMUNOLOGY (2014)
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy
Pierre G. Coulie et al.
NATURE REVIEWS CANCER (2014)
Chemotherapy Alters Monocyte Differentiation to Favor Generation of Cancer-Supporting M2 Macrophages in the Tumor Microenvironment
Eveline M. Dijkgraaf et al.
CANCER RESEARCH (2013)
Inducers of immunogenic cancer cell death
Aleksandra M. Dudek et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2013)
Human CD4+CD25+Regulatory T Cells Are Sensitive to Low Dose Cyclophosphamide: Implications for the Immune Response
Daniel Heylmann et al.
PLOS ONE (2013)
Effects of conventional therapeutic interventions on the number and function of regulatory T cells
Mario Roselli et al.
ONCOIMMUNOLOGY (2013)
The Immunological Impact of Neoadjuvant Chemotherapy on the Tumor Microenvironment of Esophageal Squamous Cell Carcinoma
Takahiro Tsuchikawa et al.
ANNALS OF SURGICAL ONCOLOGY (2012)
Premortem autophagy determines the immunogenicity of chemotherapy-induced cancer cell death
Isabelle Martins et al.
AUTOPHAGY (2012)
Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer
Makiko Ono et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Defining the Molecular Signature of Chemotherapy-Mediated Lung Tumor Phenotype Modulation and Increased Susceptibility to T-Cell Killing
Sofia R. Gameiro et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2012)
The chemotherapeutic drug oxaliplatin differentially affects blood DC function dependent on environmental cues
Jurjen Tel et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Chemotherapy broadens the range of tumor antigens seen by cytotoxic CD8+ T cells in vivo
Connie Jackaman et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
A reduction of recipient regulatory T cells by cyclophosphamide contributes to an anti-tumor effect of nonmyeloablative allogeneic stem cell transplantation in mice
Ario Takeuchi et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Application of paclitaxel in low non-cytotoxic doses supports vaccination with melanoma antigens in normal mice
Alexandra Sevko et al.
JOURNAL OF IMMUNOTOXICOLOGY (2012)
Alterations in tumor necrosis factor signaling pathways are associated with cytotoxicity and resistance to taxanes: a study in isogenic resistant tumor cells
Jason A. Sprowl et al.
BREAST CANCER RESEARCH (2012)
Chemotherapy Induces Intratumoral Expression of Chemokines in Cutaneous Melanoma, Favoring T-cell Infiltration and Tumor Control
Michelle Hong et al.
CANCER RESEARCH (2011)
Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages
Ilia N. Buhtoiarov et al.
IMMUNOLOGY (2011)
Gemcitabine depletes regulatory T-cells in human and mice and enhances triggering of vaccine-specific cytotoxic T-cells
Lorna Rettig et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival
Sylvain Ladoire et al.
JOURNAL OF PATHOLOGY (2011)
Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemoimmunotherapy
Ioannis Alagkiozidis et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress
I. Martins et al.
ONCOGENE (2011)
Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice
Mickael Michaud et al.
SCIENCE (2011)
Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer
Nathan R. West et al.
BREAST CANCER RESEARCH (2011)
Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs
Takeshi Nakahara et al.
BLOOD (2010)
Differential effects of Paclitaxel on dendritic cell function
Justin John et al.
BMC IMMUNOLOGY (2010)
Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses
W. M. Liu et al.
BRITISH JOURNAL OF CANCER (2010)
Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice
Lukas W. Pfannenstiel et al.
CELLULAR IMMUNOLOGY (2010)
A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers
Krithika N. Kodumudi et al.
CLINICAL CANCER RESEARCH (2010)
Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
Carsten Denkert et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Cyclophosphamide Induces Dynamic Alterations in the Host Microenvironments Resulting in a Flt3 Ligand-Dependent Expansion of Dendritic Cells
Mohamed L. Salem et al.
JOURNAL OF IMMUNOLOGY (2010)
Administration of Cyclophosphamide Changes the Immune Profile of Tumor-bearing Mice
Pu Liu et al.
JOURNAL OF IMMUNOTHERAPY (2010)
Secondary fibrosarcoma of the brain stem treated with cyclophosphamide and Imatinib
Daniela Alexandru et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Immunogenic death of colon cancer cells treated with oxaliplatin
A. Tesniere et al.
ONCOGENE (2010)
Immune Response During Therapy With Cisplatin or Radiation for Human Papillomavirus-Related Head and Neck Cancer
William C. Spanos et al.
ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY (2009)
Human leukocyte antigen class I expression is an independent prognostic factor in advanced ovarian cancer resistant to first-line platinum chemotherapy
M. Shehata et al.
BRITISH JOURNAL OF CANCER (2009)
Cisplatin primes murine peritoneal macrophages for enhanced expression of nitric oxide, proinflammatory cytokines, TLRs, transcription factors and activation of MAP kinases upon co-incubation with L929 cells
Puja Chauhan et al.
IMMUNOBIOLOGY (2009)
Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients
Paola Nistico et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Regular Dose of Gemcitabine Induces an Increase in CD14+ Monocytes and CD11c+ Dendritic Cells in Patients with Advanced Pancreatic Cancer
Atsuko Soeda et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2009)
Timed Sequential Treatment With Cyclophosphamide, Doxorubicin, and an Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor-Secreting Breast Tumor Vaccine: A Chemotherapy Dose-Ranging Factorial Study of Safety and Immune Activation
Leisha A. Emens et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Chemotherapeutic Agents in Noncytotoxic Concentrations Increase Antigen Presentation by Dendritic Cells via an IL-12-Dependent Mechanism
Galina V. Shurin et al.
JOURNAL OF IMMUNOLOGY (2009)
Recovery from Cyclophosphamide-Induced Lymphopenia Results in Expansion of Immature Dendritic Cells Which Can Mediate Enhanced Prime-Boost Vaccination Antitumor Responses In Vivo When Stimulated with the TLR3 Agonist Poly(I:C)
Mohamed L. Salem et al.
JOURNAL OF IMMUNOLOGY (2009)
The Immune Adjuvant Properties of Front-line Carboplatin-Paclitaxel: A Randomized Phase 2 Study of Alternative Schedules of Intravenous Oregovomab Chemoimmunotherapy in Advanced Ovarian Cancer
Patricia Braly et al.
JOURNAL OF IMMUNOTHERAPY (2009)
Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations
Ramon Kaneno et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2009)
Influence of cyclophosphamide and its metabolic products on the activity of peritoneal macrophages in mice
Krzysztof Bryniarski et al.
PHARMACOLOGICAL REPORTS (2009)
Influence of cyclophosphamide and its metabolic products on the activity of peritoneal macrophages in mice
Krzysztof Bryniarski et al.
PHARMACOLOGICAL REPORTS (2009)
Tumor-infiltrating lymphocytes and perforation in colon cancer predict positive response to 5-fluorouracil chemotherapy
Melinda Morris et al.
CLINICAL CANCER RESEARCH (2008)
Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: A pilot study of safety, feasibility, and immune activation
Dan Laheru et al.
CLINICAL CANCER RESEARCH (2008)
Pretreatment with cisplatin enhances E7-specific CD8+ T-cell mediated antitumor immunity induced by DNA vaccination
Chih-Wen Tseng et al.
CLINICAL CANCER RESEARCH (2008)
Chemotherapy and tumor immunity: an unexpected collaboration
Leisha A. Emens
FRONTIERS IN BIOSCIENCE-LANDMARK (2008)
Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens
Mark E. Dudley et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Increase of CD4+CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma:: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+CD25+ T lymphocytes
S. Audia et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2007)
Taxol increases the amount and T cell-activating ability of self-immune stimulatory multimolecular complexes found in ovarian cancer cells
Naotake Tsuda et al.
CANCER RESEARCH (2007)
Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications
Radek Spisek et al.
BLOOD (2007)
Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
Francois Ghiringhelli et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration
Laura Bracci et al.
CLINICAL CANCER RESEARCH (2007)
Calreticulin exposure dictates the immunogenicity of cancer cell death
Michel Obeid et al.
NATURE MEDICINE (2007)
Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model
C. Bauer et al.
GUT (2007)
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
Jerom Galon et al.
SCIENCE (2006)
Cancer Therapy-Induced Residual Bone Marrow Injury: Mechanisms of Induction and Implication for Therapy
Yong Wang et al.
CURRENT CANCER THERAPY REVIEWS (2006)
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
N Casares et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas
JMD Plate et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2005)
Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide
L Höltl et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2005)
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma
ME Dudley et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative
F Ghiringhelli et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2004)
Augmentation of chemotherapy-induced cytokine production by expression of the platelet-activating factor receptor in a human epithelial carcinoma cell line
M Darst et al.
JOURNAL OF IMMUNOLOGY (2004)
Exposure to paclitaxel or vinblastine down-regulates CD11a and CD54 expression by P815 mastocytoma cells and renders the tumor cells resistant to killing by nonspecific cytotoxic T lymphocytes induced with anti-CD3 antibody
CL Zhao et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2003)
Increased expression of CEA and MHC class I in colorectal cancer cell lines exposed to chemotherapy drugs
S Ohtsukasa et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2003)
Cellular and molecular aspects of drugs of the future: oxaliplatin
AM Di Francesco et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2002)
Mouse toll-like receptor 4•MD-2 complex mediates lipopolysaccharide-mimetic signal transduction by taxol
K Kawasaki et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
